Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01976156 · ClinicalTrials.gov registry record · NA
The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT01976156 is a NA study that has completed, run by Yale University. The registered enrollment target is 100 participants.
The verdict
NCT01976156, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The aims of this project are to determine if dietary supplementation with NOPE-EGCG (PhosphoLeantm, 30mg NOPE+20mg EGCG per capsule) can: * rescue striatal function, * increase adherence to a diet, * reduce weight-gain after a diet, * improve performance on impulsivity, go/no-go tasks, and negative outcome learning, and * shift fat and sweet preference in overweight/obese human subjects Secondary hypotheses: Baseline brain; perceptual and cognitive measures will be associated with diet, insulin sensitivity and may vary with genotype (TaqA1 1A polymorphism).
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT PhosphoLean
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01976156
The ClinicalTrials.gov registry entry for NCT01976156 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01976156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01976156 about?
NCT01976156 is a clinical study titled "The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity". The aims of this project are to determine if dietary supplementation with NOPE-EGCG (PhosphoLeantm, 30mg NOPE+20mg EGCG per capsule) can: * rescue striatal function, * increase adherence to a diet, * reduce weight-gain after a diet, * improve performance on impulsivity, go/no-go tasks, and negative...
What is the current status of trial NCT01976156?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2013-10. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01976156?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), PhosphoLean (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01976156?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.